Palliative Care Benefits Vary Depending on Providers, Timing

Nivolumab Boosted Survival in Relapsed Mesothelioma

KEYNOTE-598: Dual PD-1 and CTLA-4 Checkpoint Blockade Confers No Therapeutic Benefit Beyond PD-1 Blockade Alone in PD-L1–Positive NSCLC

LCMC3 Findings Indicate Neoadjuvant Atezolizumab Safe, Efficacious in Resectable Stage IB-IIIB NSCLC

Genetically Tailored Treatment Approach Did Not Improve Survival in Stage II-III NSCLC

IASLC Establishes Global Molecular Database for Thoracic Malignancies: A Call for Data

IASLC Journals Share Exciting Milestones on Metrics Journeys

Renowned Medical Oncologist, Investigator to Take Reins at IASLC in March

Introducing the New ILCN

IASLC’s Global Reach a Strength on the Road to a Cure for Lung Cancer

IASLC Releases Position Statement on Air Pollution on Earth Day

IASLC Responds to Call for Evidence